Claims
- 1. A stabilized IGFBP-3, comprising the sequence of FIG. 1, wherein position 116 is changed to an amino acid other than aspartate.
- 2. The stabilized IGFBP-3 of claim 1, wherein position 116 is changed to glutamic acid.
- 3. A stabilized IGFBP-3, comprising the sequence of FIG. 1, wherein position 135 is changed to an amino acid other than aspartate.
- 4. The stabilized IGFBP-3 of claim 3, wherein position 135 is changed to glutamic acid.
- 5. The stabilized IGFBP-3 of claim 4, wherein residue 116 is changed to an amino acid other than aspartate.
- 6. The stabilized IGFBP-3 of claim 5, wherein residue 116 is changed to glutamic acid.
- 7. A nuclear localization signal (NLS) variant IGFBP-3 wherein the NLS sequence is altered.
- 8. The NLS variant IGFBP-3 of claim 7 comprising the sequence of FIG. 1 wherein residue 228 is altered to an amino acid other than lysine.
- 9. The NLS variant IGFBP-3 of claim 8 wherein residue 228 is altered to glutamic acid.
- 10. The NLS variant IGFBP-3 of claim 7, wherein residue 230 is altered to an amino acid other than arginine.
- 11. The NLS variant IGFBP-3 of claim 10, wherein residue 230 is altered to glycine.
- 12. The NLS variant IGFBP-3 of claim 7, wherein residue 228 is altered to an amino acid other than lysine and residue 230 is altered to a residue other than arginine.
- 13. The NLS variant IGFBP-3 of claim 12, wherein residue 228 is altered to glutamic acid and residue 230 is altered to glycine.
- 14. An N-terminally extended insulin-like growth factor binding protein 3 (IGFBP-3), comprising:
an N-terminal extension sequence selected from the group consisting of nucleotide-binding sequences, peptide binding sequences, antigen or ligand binding sequences, protein hormones, growth factors and enzymes; and IGFBP-3, wherein said IGFBP-3 is linked to the carboxy terminus of said fusion partner, and wherein said N-terminal extension sequence is not DsbA, leaderless DsbA, Vibro cholerae TcpG, DsbC, or leaderless DsbC.
- 15. The N-terminally extended IGFBP-3 of claim 14, wherein said IGFBP-3 comprises the sequence of FIG. 1.
- 16. The N-terminally extended IGFBP-3 of claim 14, wherein said IGFBP-3 comprises a variant of the sequence of FIG. 1.
- 17. The N-terminally extended IGFBP-3 of claim 16, wherein said variant comprises the sequence of FIG. 1 with position 5 changed to glycine.
- 18. The N-terminally extended IGFBP-3 of claim 16, wherein said IGFBP-3 comprises an ND variant IGFBP-3.
- 19. The N-terminally extended IGFBP-3 of claim 14, wherein said N-terminal extension is a nucleotide binding sequence.
- 20. The N-terminally extended IGFBP-3 of claim 14 wherein said N-terminal extension is an enzyme.
- 21. The N-terminally extended IGFBP-3 of claim 20 wherein said enzyme is not glutathione-S-transferase or β-galactosidase.
Parent Case Info
[0001] This application claims priority to under 35 U.S.C. § 119(e) U.S. Provisional Applicaton Serial No. 60/087,559, filed Jun. 1, 1998, the contents of which are incorporated by reference in their entirety.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60087559 |
Jun 1998 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
09322484 |
May 1999 |
US |
Child |
09986944 |
Nov 2001 |
US |